Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data

Abstract

Background/Aims: The aim of the present study was to provide normative data and determine the validity of the Czech version of the Mattis Dementia Rating Scale 2 (czDRS-2) in screening for mild cognitive impairment in Parkinson's disease (PD-MCI) based on the Movement Disorder Society (MDS) Level II criteria. Methods: For validation purposes, 41 healthy controls (HC), 46 patients with PD-NI (Parkinson's disease, no impairment) and 41 patients with PD-MCI (all groups assessed by the MDS Level II criteria for PD-MCI) were matched according to age and education. Results: With screening and diagnostic cutoff scores determined at ≤139 points, the czDRS-2 showed a sensitivity of 78% and a specificity of 88% in the detection of PD-MCI versus HC and a sensitivity of 78% and a specificity of 76% in the detection of PD-MCI versus PD-NI. The AUC (95% confidence interval) for the czDRS-2 was 84% (75-93) and 82% (73-91), respectively. We report percentile values for 286 subjects from the Czech population stratified by education level. Conclusion: Our results show that the czDRS-2 is a valid instrument at Level I for screening PD-MCI and support its construct validity and diagnostic equivalence in a cross-cultural setting.

The Diagnostic Accuracy of Parkinson's Disease Mild Cognitive Impairment Battery Using the Movement Disorder Society Task Force Criteria

“…Participants (patients and paired controls) underwent a comprehensive clinical evaluation that included medical history, evaluation of functional abilities, medication status, motor status by the UPDRS Part III (UPDRS‐III), and standard MDS Level II neuropsychological assessment for the diagnosis of PD‐MCI . The neuropsychological battery at Level I (abbreviated assessment) generally consists of global scales of cognitive abilities, in the present study of the Mattis Dementia Rating Scale, Second Edition (DRS‐II) . Level II (comprehensive assessment) consisted of 10 tests in five cognitive domains; one measure from each test was derived as recommended: (1) attention and working memory (Digit Span [DS] forward from the Wechsler Adult Intelligence Scale, Third Revision [WAIS‐III] and Trail Making Test [TMT]‐A); (2) executive function (TMT‐B and Prague Stroop test interference condition); (3) language (semantic fluency [animals, clothes, and shopping] and WAIS‐III Similarities); (4) memory (Rey Auditory Verbal Learning Test [RAVLT], learning delayed recall and Family Pictures [FP] delayed recall from the Wechsler Memory Scale, Third Revision [WMS‐III]); and (5) visuospatial function (CLOX and Judgment of Line Orientation).…”

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale‐2 in Parkinson's disease

“…In contrast, the sensitivity of the DRS‐2 dropped from 87.5% to 60.3% when the determined cutoff (≤138/144) was applied to the validation cohort. Interestingly, this cutoff was lower than those previously published in PD (≤139/144 and ≤ 140/144) . Although sensitivity was somewhat improved at higher cutoffs, with the specificity approaching 50% (Supplemental Table 2).…”

Performance of Mattis dementia rating scale-Chinese Version in patients with mild cognitive impairment and Alzheimer's disease

“…The pattern of DRS scores obtained on the five domains can show qualitative differences in the cognitive profiles of different types of dementia, including Parkinson's disease (PD) [1], Huntington's disease [2], Lewy Body dementia [3] and Progressive supranuclear palsy [4]. Recently, the scale has been appled to a wider range disorders, such as mild cognitive impairment (MCI) due to PD, and schizophrenia [5].…”